DVM | Jotup

Veterinarians Take Over Nashville in November for A Different Way to CE!

Retrieved on:

Friday, January 5, 2024

Rascal Flatts, Conference, Learning, Christian Veterinary Mission, Student, CVM, CE, DVM, Knowledge, Convention center, Veterinary medicine, Veterinarian, Organization

LANCASTER, S.C., Jan. 5, 2024 /PRNewswire/ -- Christian Veterinary Mission (CVM) Veterinary Conference: "A Different Way to CE!" wrapped with more than 900 guests in attendance. The third annual conference, sponsored by Nutramax Laboratories Veterinary Sciences, Inc., saw its highest attendance to date, as veterinary professionals and students from around the world converged at the Gaylord Opryland Resort & Convention Center. Attendees enjoyed one-of-a-kind fellowship with other veterinary professionals, superior entertainment, and stretched their knowledge with educational sessions designed just for them!

Key Points:

LANCASTER, S.C., Jan. 5, 2024 /PRNewswire/ -- Christian Veterinary Mission (CVM) Veterinary Conference: "A Different Way to CE!"
Attendees enjoyed one-of-a-kind fellowship with other veterinary professionals, superior entertainment, and stretched their knowledge with educational sessions designed just for them!
In addition to CE, guests were treated to a private concert from Gary LeVox, front man for the multi-award-winning super group, Rascal Flatts!
Interested veterinary professionals and students can click here to sign up for "A Different Way to CE" 2024!

This Blood Donor Month, Consider a Donation from Your Pet

Retrieved on:

Thursday, January 4, 2024

Pet, Partnership, Emergency, Cat, Blood, Human, Dog, Animal, DVM, Knowledge, Pharmaceutical industry

TAMPA, Fla., Jan. 4, 2024 /PRNewswire/ -- To commemorate Blood Donor Month, which takes place each January, BluePearl is encouraging donations from pets across the country to alleviate the shortage of available blood products nationwide. Just as humans require blood transfusions for medical conditions or emergencies, the same is true for pets and due to the increased demand for emergency and specialty veterinary care the need for pet blood donations is greater than ever.

Key Points:

Just as humans require blood transfusions for medical conditions or emergencies, the same is true for pets and due to the increased demand for emergency and specialty veterinary care the need for pet blood donations is greater than ever.
As with humans, cats and dogs can donate blood several times each year, with BluePearl recommending 12-week intervals between each donation.
"Our objective is to raise awareness that pet blood donations are an option and hopefully to encourage pet owners to take their cat or dog to donate if they are eligible.
To learn more about BluePearl, the BluePearl Blood Banking Program and requirements for animals donating blood, visit bluepearlvet.com /blood-bank/ or follow us on Instagram , Facebook or LinkedIn .

iBio Amends and Extends Maturity of Credit Agreement

Retrieved on:

Tuesday, December 26, 2023

Immunotherapy, Sale, Credit, Research, CDMO, CGMP, SAN, DVM, Woodforest National Bank, Acceleration

BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated November 1, 2021 (the “Agreement”), extending the Agreement’s maturity date from December 31, 2023 to the earlier March 29, 2024, or the acceleration of maturity of the term loan in accordance with the Credit Agreement.

Key Points:

– Extends maturity date to March 29, 2024 –
BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated November 1, 2021 (the “Agreement”), extending the Agreement’s maturity date from December 31, 2023 to the earlier March 29, 2024, or the acceleration of maturity of the term loan in accordance with the Credit Agreement.
“We are pleased to have worked constructively with Woodforest to execute this amendment and extension of the maturity date of our existing Credit Agreement,” said Martin Brenner, DVM, Ph.D., iBio’s Chief Executive Officer and Chief Scientific Officer.
“This provides us with additional financial flexibility to focus on the sale of our cGMP biologics manufacturing facility in Texas concurrent with the continued advancement of our AI drug discovery platform and immunotherapy pipeline out of our research and development center in California.”

Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis

Retrieved on:

Wednesday, December 6, 2023

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Gallant Therapeutics, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the launch of a pivotal study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis (FCGS), the JEDI study.

Key Points:

SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the launch of a pivotal study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis (FCGS), the JEDI study .
More than 50% of these cats do not respond to therapy (are refractory) and are euthanized or die.
In pilot studies1, Gallant’s investigational stem cell therapy has been demonstrated effective for refractory FCGS, improving painful lesions and quality of life, allowing these cats to live longer and healthier lives.
The multicenter pivotal JEDI study includes veterinary dental specialist sites across the United States and is currently enrolling cats under an FDA-concurred protocol.

dvm360® and Chewy Health announce the 2023 Innovator of the Year Award™ recipients

Retrieved on:

Monday, December 4, 2023

Carozza, Pet, Partnership, RVT, LVT, Paraprofessional, DVM, Oncology, MBA, Certification, Spectrum, Animal, VCA, Veterinary medicine, USDA, Social media, VTS, Organization, CAT

CRANBURY, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- dvm360 , the number one multimedia platform in the veterinary industry, in partnership with Chewy Health, the dedicated pet health care arm of Chewy, is thrilled to announce that the 2023 winners for the dvm360 2023 Innovator of the Year Award program have been revealed!

Key Points:

CRANBURY, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- dvm360 , the number one multimedia platform in the veterinary industry, in partnership with Chewy Health, the dedicated pet health care arm of Chewy, is thrilled to announce that the 2023 winners for the dvm360 2023 Innovator of the Year Award program have been revealed!
The 2023 dvm360 and Chewy Health Innovator of the Year Award recipients were announced and honored at the dvm360 Fetch Long Beach conference in Long Beach, California, which took place December 1-3, 2023.
I am excited to celebrate our 2023 winners along with our generous partners at Chewy Health!” said Adam Christman, DVM, MBA, chief veterinary officer at dvm360.
You can learn more about the Chewy Health and dvm360 Innovator of the Year Award program here .

PetVivo Holdings, Inc. to Exhibit at American Association of Equine Practitioners Conference in San Diego, California

Retrieved on:

Tuesday, November 21, 2023

AAEP, Limp, CEHM, Osteoarthritis, MBA, Joseph Manning, Animal, DVM, Horse, Veterinarian, Therapy, ACVS, San Diego Convention Center

PetVivo will exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, a medical device injection of sterilized, extra-cellular matrix microparticles that are lubricious and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis.

Key Points:

PetVivo will exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology, a medical device injection of sterilized, extra-cellular matrix microparticles that are lubricious and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis.
The AAEP is the largest veterinary equine conference that services the United States, and normally plays host to more than 5,000 participants including many of the top industry professionals.
If you would like to attend the presentations by Dr. Yarbrough and Dr. Manning the details are provided below.
Location: San Diego Convention Center in San Diego, California
For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact [email protected] or visit https://petvivo.com/ and https://sprynghealth.com/ .

ECM Therapeutics Announces Collaboration with the Louis J. Fox Center at the University of Pittsburgh Vision Institute to Advance Cutting-edge Technology for Optic Nerve Repair

Retrieved on:

Tuesday, December 19, 2023

Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine .

Key Points:

Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute led by José-Alain Sahel, MD, a distinguished professor and chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine .
MBV are a distinct class of extracellular vesicles embedded within the extracellular matrix (ECM) that are enriched in pro-resolving lipids, anti-inflammatory protein and miRNA cargo.
The combined resources of the two entities will address the formidable challenge of restoring vision following optic nerve damage.
For more information on ECM Therapeutics, please visit www.ecmtherapeutics.com or follow the company on LinkedIn .

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Retrieved on:

Tuesday, December 19, 2023

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022 .

Key Points:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022 .
Following a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization.
Innate Pharma is eligible for up to €1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.
Valeria Fantin, Ph.D., Global Head of Oncology Research at Sanofi, states: “Sanofi is pleased with our collaboration with Innate and continues to be excited at the potential of investigational NK Cell Engagers.

OncoK9® Liquid Biopsy Test Can be Used for Cancer Monitoring in Dogs Across a Variety of Cancer Types, AJVR Publication Shows

Retrieved on:

Thursday, December 28, 2023

SAN DIEGO, Dec. 28, 2023 /PRNewswire/ -- PetDx® – The Liquid Biopsy Company for Pets™ published a study today showing that its previously clinically validated OncoK9® multi-cancer early detection test for dogs using next-generation sequencing (NGS) technology can detect genomic alterations indicative of residual disease and cancer recurrence in cell-free DNA of dogs previously treated by surgery for a variety of cancer types.

Key Points:

Appearing in the American Journal of Veterinary Research, the study evaluated OncoK9® results from blood samples collected prospectively between 2019 and 2022 as well as corresponding clinical management and outcome data.
Over 50 dogs that had received a definitive cancer diagnosis across 12 different cancer types were included in the analysis, and individual subjects underwent OncoK9® testing and clinical evaluations for a period of up to one year.
Our multi-year longitudinal study documents, for the first time, the application of this NGS technology for cancer monitoring in veterinary medicine."
"This latest study represents an important addition to our scientific portfolio, and indicates that OncoK9® can be used by veterinarians as a noninvasive adjunct tool to manage cancer patients in the post-diagnosis setting."

Experts on AI, the "Mystery Dog Illness" and the State of Pet Care in Ukraine to Speak at VMX 2024

Retrieved on:

Wednesday, December 20, 2023

ORLANDO, Fla., Dec. 20, 2023 /PRNewswire/ -- Jan. 13 -17, 2024, the North American Veterinary Community (NAVC) will host VMX 2024 in Orlando, FL, setting the direction for veterinary medicine in the new year and providing industry professionals with more than 800 continuing education and scientific sessions presented by world-renowned veterinary leaders. VMX features subject matter experts on the top current events in veterinary medicine to help veterinary professionals expand their skills and be on the cutting edge of what's new and notable.

Key Points:

VMX features subject matter experts on the top current events in veterinary medicine to help veterinary professionals expand their skills and be on the cutting edge of what's new and notable.
VMX 2024 will feature world-renowned animal healthcare experts who are available for interviews.
His session takes place at 4:15 p.m. in the VMX Sound Stage, Booth 315, in the Expo Hall.
His session takes place at 1-2 p.m. January 14 in the VMX Sound Stage Booth 315 in the Expo Hall.